/K I L L K I L L K I L L — Celgene Corporation/
June 15, 2007
We are advised by Celgene Corporation that journalists and other readers should disregard the news release, REVLIMID(R) Granted Full Marketing Authorization for Treatment of Multiple Myeloma in the European Union, issued earlier today over PR Newswire. The drug remains under review by EMEA and has not been approved.
Celgene Corporation
Web site: http://www.celgene.com/http://www.revlimid.com/